---
document_datetime: 2023-09-21 17:20:46
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/coagadex-epar-all-authorised-presentations_en.pdf
document_name: coagadex-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7881436
conversion_datetime: 2025-12-19 07:05:21.552728
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form                           | Route of Administration   | Immediate Packaging                         | Content (concentration)         | Pack size                         |
|------------------|-------------------|------------|-----------------------------------------------|---------------------------|---------------------------------------------|---------------------------------|-----------------------------------|
| EU/1/16/1087/001 | Coagadex          | 250 IU     | Powder and solvent for solution for injection | Intravenous use           | Powder: vial (glass); Solvent: vial (glass) | Powder: 250 IU; Solvent: 2.5 ml | 1 vial + 1 vial + transfer device |
| EU/1/16/1087/002 | Coagadex          | 500 IU     | Powder and solvent for solution for injection | Intravenous use           | Powder: vial (glass); Solvent: vial (glass) | Powder: 500 IU; Solvent: 5 ml   | 1 vial + 1 vial + transfer device |